These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35178611)

  • 41. The Use of Integrase Strand Transfer Inhibitors to Treat HIV in Pregnancy.
    Nissim O; Lazenby GB
    J Midwifery Womens Health; 2021 May; 66(3):403-406. PubMed ID: 34166578
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Mbhele N; Chimukangara B; Gordon M
    Int J Antimicrob Agents; 2021 May; 57(5):106343. PubMed ID: 33852932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

  • 44. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
    N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
    Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
    N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Safety Considerations of Integrase Strand Transfer Inhibitors in the Older Population Living with HIV.
    Vider E; Gavioli EM
    Drugs Aging; 2021 Nov; 38(11):967-975. PubMed ID: 34494229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in functional connectivity in people with HIV switching antiretroviral therapy.
    Toniolo S; Cercignani M; Mora-Peris B; Underwood J; Alagaratnam J; Bozzali M; Boffito M; Nelson M; Winston A; Vera JH
    J Neurovirol; 2020 Oct; 26(5):754-763. PubMed ID: 32500477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
    Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
    J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
    Elliot E; Chirwa M; Boffito M
    Curr Opin Infect Dis; 2017 Feb; 30(1):58-73. PubMed ID: 27798496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
    Brooks KM; Sherman EM; Egelund EF; Brotherton A; Durham S; Badowski ME; Cluck DB
    Pharmacotherapy; 2019 May; 39(5):576-598. PubMed ID: 30860610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV integrase inhibitors: 20-year landmark and challenges.
    Métifiot M; Marchand C; Pommier Y
    Adv Pharmacol; 2013; 67():75-105. PubMed ID: 23885999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
    Alessandri-Gradt E; Collin G; Tourneroche A; Bertine M; Leoz M; Charpentier C; Unal G; Descamps D; Plantier JC
    J Antimicrob Chemother; 2017 Sep; 72(9):2431-2437. PubMed ID: 28859447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
    Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R;
    Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.
    Park TE; Mohamed A; Kalabalik J; Sharma R
    Expert Rev Anti Infect Ther; 2015; 13(10):1195-212. PubMed ID: 26293294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparable
    Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
    Han YS; Mesplède T; Wainberg MA
    Infect Genet Evol; 2016 Dec; 46():286-291. PubMed ID: 27353185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
    Yang LL; Li Q; Zhou LB; Chen SQ
    Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.